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Abstract
Purpose Diarrhea-predominant irritable bowel syndrome
(IBS-D) can considerably impact patients’ lives. Patient-
reported symptoms are crucial in understanding the diag-
nosis and progression of IBS-D. This study psychometrically
evaluates the newly developed IBS-D Daily Symptom Diary
and Symptom Event Log (hereafter, ‘‘Event Log’’) accord-
ing to US regulatory recommendations.
Methods A US-based observational field study was con-
ducted to understand cross-sectional psychometric proper-
ties of the IBS-D Daily Symptom Diary and Event Log.
Analyses included item descriptive statistics, item-to-item
correlations, reliability, and construct validity.
Results The IBS-D Daily Symptom Diary and Event Log
had no items with excessive missing data. With the
exception of two items (‘‘frequency of gas’’ and ‘‘acci-
dents’’), moderate to high inter-item correlations were
observed among all items of the IBS-D Daily Symptom
Diary and Event Log (day 1 range 0.67–0.90). Item scores
demonstrated reliability, with the exception of the ‘‘fre-
quency of gas’’ and ‘‘accidents’’ items of the Diary and
‘‘incomplete evacuation’’ item of the Event Log. The pat-
tern of correlations of the IBS-D Daily Symptom Diary and
Event Log item scores with generic and disease-specific
measures was as expected, moderate for similar constructs
and low for dissimilar constructs, supporting construct
validity. Known-groups methods showed statistically sig-
nificant differences and monotonic trends in each of the
IBS-D Daily Symptom Diary item scores among groups
defined by patients’ IBS-D severity ratings (‘‘none’’/
‘‘mild,’’ ‘‘moderate,’’ or ‘‘severe’’/‘‘very severe’’), sup-
porting construct validity.
Conclusions Initial psychometric results support the reli-
ability and validity of the items of the IBS-D Daily
Symptom Diary and Event Log.
Keywords Patient-reported outcome  Diarrhea-
predominant IBS  IBS-D  Psychometric analysis
Introduction
Diarrhea-predominant irritable bowel syndrome (IBS-D) is
a common and burdensome condition, especially in indi-
viduals with moderate to severe IBS-D, who suffer sig-
nificantly impaired quality of life and high healthcare costs
[1–3]. As no biomarkers or clinical measures of disease
activity are currently available in IBS-D, diagnosis and
treatment rely on direct patient report of signs and symp-
toms. IBS-D diagnostic criteria rely exclusively on the
evaluation of symptoms, and the recently published US
Food and Drug Administration (FDA) IBS guidance [4] on
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the design of IBS interventional trials recommends that
primary endpoints in IBS-D trials be made up of patient-
reported symptom assessments [5, 6].
Historically, clinical trial primary endpoints in IBS have
relied on single-item assessments that ask patients to judge
whether they have experienced ‘‘adequate symptom relief’’
or ‘‘satisfactory relief’’ over the entire trial [4]. The limita-
tions of such single-item assessments of a patient’s symptom
experience in terms of covering the breadth of IBS-D
symptomology have been well documented [4, 7, 8]. None of
these measures meet the FDA patient-reported outcome
(PRO) guidance [9] in terms of content validity, nor do they
adhere to the agency’s roadmap for clinical outcomes of
assessment [10, 11]. In addition, the FDA no longer con-
siders a global measure of change to be adequate as a primary
endpoint [4, 9]. Consequently, the FDA’s IBS guidance
highlights the need to develop multi-item, patient-reported
measures in line with the agency’s PRO guidance. While
there are established measures such as the IBS-Severity
Scoring System (IBS-SSS) [12] and the IBS-Quality of Life
Questionnaire (IBS-QOL), these historical measures were
not intended to investigate benefits of treatment in the clin-
ical setting, nor do they meet the needs of the IBS-D popu-
lation (i.e., context of use) [13]. Moreover, they do not meet
the rigor as set forth by the FDA PRO guidance [9]. New
measures should be developed based on qualitative research
with patients and must be designed to capture the cardinal
symptoms of IBS-D, including abdominal pain, bowel
function, and bloating [7, 8, 14].
To meet this need, the new IBS-D Daily Symptom Diary
and Symptom Event Log (hereafter, ‘‘Event Log’’) was
developed via qualitative research among IBS-D patients,
in accordance with the FDA PRO guidance [9]. A full
account of the qualitative development of this instrument is
provided elsewhere [15]. This prior research provides
evidence that the instrument’s items demonstrate content
validity and assess the full measurement continuum. The
hypothesized conceptual framework based on the qualita-
tive research is provided in Fig. 1.
Once established through qualitative research that a new
PRO measures all concepts that are clinically relevant and
important to patients, in a manner that patients understand
and can respond to, the next step is to evaluate the initial
measurement properties of the instrument. This evaluation
can then be used to develop a scoring algorithm, as well as
guide potential item deletion. This article presents initial
results generated from a US-based, multicenter, non-in-
terventional observational study regarding the cross-sec-
tional psychometric properties of the IBS-D Daily
Symptom Diary and Event Log.
Methods
Patients
Patients with clinician-verified diagnoses of mild, mod-
erate, or severe IBS-D (per Rome III criteria) were
recruited into a US-based, multicenter, and non-inter-
ventional observational study. The targeted distribution
of the sample population was *50 patients with mild,
100 with moderate, and 50 with severe disease (based on
clinician reports). Patients were recruited from general
practice and gastroenterology clinics between June 2012
and November 2012 and were eligible for inclusion if
they met the inclusion and exclusion criteria outlined in
Table 1.
Written informed consent was obtained from all patients
prior to inclusion in the study. All study forms were
approved by a centralized, independent ethics committee,
in accordance with the revised Declaration of Helsinki
[16]. Patients were free to discontinue participation in the
study at any time.
Demographics and clinician IBS-D severity rating
Clinicians completed a case report form during an initial
screening visit, confirming that the patient had a diagnosis
of IBS-D (per Rome III criteria) and met all inclusion and
exclusion criteria. Clinicians also assessed the patient’s
IBS-D symptom severity using a 5-point graded scale of
‘‘very mild,’’ ‘‘mild,’’ ‘‘moderate,’’ ‘‘severe,’’ or ‘‘very
severe.’’ Once patients were screened into the study, they
were asked to complete a baseline demographic and health
information form.
Patient-reported outcomes
To evaluate the newly developed symptom diary, several
well-established PRO instruments were included in the
study, including generic and disease-specific measures of
symptoms and impact on health-related quality of life
(HRQoL). Patients completed seven PRO instruments: the
newly developed IBS-D Daily Symptom Diary and Event
Log (described below) [15]; IBS-SSS [12]; the 12-item
Short-Form Health Survey (SF-12) [17]; IBS-QOL instru-
ment [13]; the Patient Global Impression of Severity (PGI-
S); and 24-h recall and 7-day recall versions of the Patient
Global Impression of change (PGI-C) [18]. The IBS-SSS,
the IBS-QOL, the SF-12, the PGI-S, and the PGI-C are
described in Table 2.
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IBS-D Daily Symptom Diary
The IBS-D Daily Symptom Diary is a 7-item PRO diary
measuring abdominal pain, stomach pain, abdominal
pressure, bloating, abdominal cramping, frequency of gas,
and the occurrence of accidents. Five of the symptoms are
rated on an 11-point numerical rating scale with 0
representing absence of symptoms and 10 representing
severe symptoms. Frequency of gas is measured on an
ordinal scale from ‘‘none of the time’’ to ‘‘all of the time,’’
and the occurrence of accidents has a ‘‘Yes/No’’ response
option. The recall period for all items is the past 24 h.
Daily and weekly (i.e., means) scores were utilized for
each item for analyses.






































Fig. 1 Hypothesized conceptual framework
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IBS-D Symptom Event Log
The IBS-D Symptom Event Log consists of three questions
which ask the patient to rate, with respect to each indi-
vidual bowel movement, the immediacy of need (1 = ‘‘no
immediate need’’ to 5 = ‘‘extreme immediate need’’),
consistency of the bowel movement (pictorial 8-point
scale: 1 = ‘‘like marbles or hard rocks’’ to 8 = ‘‘just liq-
uid’’), and whether the bowels were completely emptied
(‘‘Yes/No’’). All items are completed after each bowel
movement, and the date and time of each bowel movement
were recorded. Daily and weekly (i.e., means) scores were
utilized for each item for analyses.
Administration of PRO instruments
All data were collected on a paper case report form. Center
personnel were trained to instruct patients in a standardized
way to reduce data collection errors and enhance
questionnaire completion compliance. Clinician severity
ratings and patient demographic and health information
were collected at baseline (day 1). The PRO measures
administered in the study were assessed across two inter-
vals: period 1 (study weeks 1 and 2; days 1–14) and period
2 (study weeks 3 and 4; days 15–28). The schedule of
assessment is summarized in Table 3.
All data were manually entered into a password-pro-
tected database; standards of quality control, including
proportional double data entry, were observed. Date and
time of completion were captured for the daily diary. All
eligible patients who completed at least one item of the
IBS-D PRO instruments at day 1, period 1 were included in
the analysis population.
Statistical methods
Psychometric analyses were performed to evaluate the
item-level measurement properties of the instrument.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
The patient is 18 years of age or older
The patient is fluent in US English and capable of comprehending and signing an informed consent form for participation
The patient has a clinician-confirmed diagnosis of IBS-D






The patient has experienced IBS-D symptoms for at least 6 months prior to diagnosis
The patient has experienced recurrent abdominal pain or discomfort associated with two of the three following features, at least 3 days a
month, for the last 3 months
• Improvement with defecation
• Onset associated with a change in frequency of stool
• Onset associated with a change in form (appearance) of stool
The patient has experienced loose (mushy) or watery stools (type 6 or 7 on the Bristol Stool Form Scale) in at least 25 % of bowel movements
and hard or lumpy stool in fewer than 25 % of bowel movements in the absence of use of anti-diarrheals or laxatives in the last 3 months
Exclusion criteria
The patient has an organic disease or functional gastrointestinal syndrome, other than IBS, potentially affecting the digestive tract passage or
colonic function, including structure, obstruction, or ileus
The patient has a bowel movement characterized as a Bristol Stool Form Scale of 3 or less in the last 7 days prior to enrollment
The patient has benign polyps or colonic diverticulosis judged to have an influence on the digestive tract passage or colonic function
Does the patient have a history of surgical resection of stomach, small intestine, or large intestine (excluding resection of appendix or benign
polyps)?
The patient has a history of ischemic colitis, history of unexplained blood passage per rectum
The patient has uncontrolled lactose intolerance, or is the patient receiving radiotherapy for abdominal disease?
The patient has a history of drug or alcohol abuse within past year or history of major psychiatric disorders or current significant depression or
anxiety
The patient has cardiovascular, pulmonary, endocrine, metabolic, hematologic, neurologic, or gastrointestinal (excluding IBS) disease
The patient has a history of thyroid dysfunction
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Demographic and health information of the study popula-
tion was summarized using descriptive statistics. Contin-
uous variables were described by presenting the frequency,
mean, standard deviation, median, minimum, maximum,
and instances of missing data. Categorical variables were
described by presenting the number and percentage of
patients in each category and the number of missing data
(the percentage in each category was calculated including
the proportion of patients with missing values). Quality of
completion was assessed for the IBS-D Daily Symptom
Diary and Event Log at day 1 through day 15 as the number
and percentage of patients missing responses. Items with
missing data [10 % were flagged and considered candi-
dates for deletion. If[10 % of patients endorsed the lowest
or highest categories on a given item on the IBS-D Daily
Symptom Diary and Event Log, the item was investigated
for floor or ceiling effects, respectively. Floor or ceiling
effects that are too pronounced could interfere with the
ability of the score to detect improvement, deterioration, or
difference between groups in a clinical trial; however, floor
and ceiling effects must be interpreted in the context of the
study sample and the condition being studied.
Inter-item correlations were evaluated for the IBS-D
Daily Symptom Diary and Event Log items. Correlations
[0.80 suggested potential redundancy and thus potential
candidates for deletion [19].
The emphasis in a psychometric study is on evaluation
of the magnitude of relationships between variables and the
overall pattern of results rather than significance testing. As
such, no adjustments are generally used for multiplicity of
tests. For many psychometric analyses, significance tests
are not traditionally used. Where specific significance tests
are used, the threshold for statistical significance was
p\ 0.05. Statistical analyses were performed for the study
using Statistical Analysis System version 9 (SAS Institute,
Cary, NC, USA).
Psychometric evaluation of the instrument: reliability
Test–retest reliability measures the stability of a score over
multiple administrations of an instrument to the same
patient [20]. The time period for assessment is critical in
chronic, symptomatic, or event-driven conditions because
response variability may be high due to the nature of the
disease. In this study, test–retest reliability was assessed by
comparing 7-day average scores for the IBS-D Daily
Symptom Diary and Event Log items between study weeks
1 and 4. The subgroup of stable patients for this analysis
Table 2 Other instruments
PRO
Name
Number of Items and item content Scoring
IBS-SSS
[12]
Five items assessing abdominal pain, abdominal distension,
bowel dysfunction, and quality of life/global well-being as
reported by patients.
The IBS-SSS total score is calculated by summing the five item
scores, resulting in a total score ranging from 0 to 500, with
higher scores reflecting higher severity of IBS
The IBS-SSS has no specified recall period
SF-12
[17]
Twelve items assessing dimensions: physical functioning, role
physical, role emotional, bodily pain, general health, vitality,
social functioning, and mental health.
Scores for each dimension are obtained by summing the
corresponding item values. The resulting scores are then
rescaled from 0 (worst possible health state measured by the
questionnaire) to 100 (best possible health state)
In addition, two summary scores, the physical component scale
(PCS-12) and the mental component scale (MCS-12), are
calculated
The SF-12 has a recall period of 1-week
IBS-QOL
[13]
Thirty-four items assessing quality of life with impact being
assessed across eight domains: dysphoria (eight items),
interference with activity (seven items), body image (four
items), health worry (three items), food avoidance (three
items), social reaction (four items), sexual (two items), and
relationships (three items)
All domain scores are converted to a 0 to 100 scale, with high
scores representative of a better health state
The summed global score is transformed to a 0-100 scale
ranging from 0 (poor quality of life) to 100 (maximum quality
of life)
The IBS-QOL has a recall period of 4 weeks
PGI-S
[18]
Item assessing the severity of IBS-D Severity is measured on a scale of 1 (none) to 5 (very severe)
scale
The PGI-S has a recall period of ‘‘currently’’
PGI-C
[18]
Item assessing level of change in IBS-D Change is measured on a scale of 1 (very much improved) to 7
(very much worse)
The PGI-C has a recall period of 1 week
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was determined using the PGI-C Week assessment at study
week 4. Patients who responded ‘‘no change’’ on this
measure were included in the test–retest analysis popula-
tion. The intraclass correlation coefficient (ICC) was used
to evaluate test–retest reliability, with ICCs [0.70 con-
sidered evidence of acceptable reliability [20].
Psychometric evaluation of the instrument: construct
validity
The construct validity of the IBS-D Daily Symptom Diary
and Event Log was examined via assessment of concurrent
and clinical/known-groups validity.
Concurrent validity was assessed via evaluating corre-
lations of the IBS-D Daily Symptom Diary and Event Log
weekly average item scores with the IBS-SSS (no specified
recall period), IBS-QOL (4-week recall period), and SF-12
(1-week recall period) at day 8. Spearman correlation
coefficients were calculated and described as strong (0.60),
moderate (0.40), or low (0.30) [21]. Low to moderate
correlations were expected between IBS-D Daily Symptom
Diary items and SF-12 scores, and moderate to high cor-
relations were expected between IBS-D Daily Symptom
Diary items and IBS-QOL and IBS-SSS scores.
Clinical (or known-groups) methods is a measure of the
ability of items to discriminate between patient subgroups
expected to respond differently based on severity of their
condition [22]. Clinician-reported IBS-D severity at base-
line was the primary classification variable used for the
assessment of clinical validity [22]. Secondary measures
used to define comparison groups for clinical validity
assessment in the present study included the PGI-S at day 8
and the derived presence or absence of flare on day 1. Flare
on a given day was defined by three or more bowel
movements recorded in the IBS-D Symptom Event Log
with a rating of 7 or 8 on the pictorial scale and an
immediate need rating of moderate or greater. A ‘‘non-flare
day’’ was defined as fewer than three bowel movements
recorded in the IBS-D Symptom Event Log with a rating
\7 on the pictorial scale and an immediate need rating of
less than moderate. Analysis of variance and t tests were
used to compare differences among groups, with differ-
ences considered significant if\0.05 level.
Results
Study population
A total of 202 patients (132 females; 65.3 %) were
enrolled in the study, with 200 patients completing the
study. Based on patient self-report, the majority of patients
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patients were mostly distributed between mild (n = 46,
22.8 %) and severe (n = 44, 21.8 %) symptoms, with few
reporting very mild (n = 5, 2.5 %) or very severe (n = 1,
0.5 %) symptoms. The mean age of the patient population
was 46.3 years ± 14.4 (range 18–79 years), and the
majority of patients were Caucasian (n = 122, 60.4 %) and
had a high school diploma or some college or other edu-
cational certification (n = 126, 62.4 %). Additional
demographic information is provided in Table 4.
IBS-D Daily Symptom Diary and Event Log
measurement properties
Descriptive statistics
Overall, patients were compliant in their completion of the
IBS-D Daily Symptom Diary and Event Log, with only 12
patients (5.9 %) with at least one missing item on any of
the 15 study days in which quality of completion was
tested. Specifically, only 5.9 % of patient had any missing
diary data during the 15-day period, with no more than 2
items being missed by a single patient on any particular
day. No patient missed items every day, nor was there a
pattern of a single item being missed. In addition, item-
level missing data were very low, with no items having
more than *4.0 % missing data. Thus, quality of com-
pletion indicated there were no patient- or item-specific
issues causing missing data and results did not suggest any
specific item as a candidate for deletion. Patients utilized
the full response scale on all items, and average symptom
severity on the IBS-D Daily Symptom Diary items ranged
between 3.6 and 4.1 across the items at the baseline (day 1)
assessment, with 26.3 % of patients reporting gas most or
all of the time and only 7.4 % experiencing an accident on
day 1. Patients reported an average of three events (bowel
movements) at baseline (day 1) on the IBS-D Symptom
Event Log, with complete emptying *54 % of the time, a
mean stool consistency of 5 (‘‘soft chunks or clumps’’), and
a mean immediacy rating of 3 (‘‘moderate immediate
need’’). One patient, recruited with severe disease, reported
42 episodes in a day, which was confirmed upon qualitative
review of the source data.
Review of the floor and ceiling effects revealed that
5–17 % of the patient population chose the lowest possible
Table 4 Demographic
characteristics at baseline (day
1)
Characteristic Total (clinical) sample (N = 202)
Age
Mean (SD) 46.3 (14.4)
Min–Max 18.0–79.0
Gender
Female, n (%) 132 (65.3)
Race
White/Caucasian, n (%) 122 (60.4)
Black/African-American, n (%) 38 (18.8)
Native Hawaiian/Pacific Islander, n (%) 3 (1.5)
Other, n (%) 39 (19.3)
Ethnicity
Not Hispanic/Latino, n (%) 176 (87.1)
Hispanic/Latino, n (%) 26 (12.9)
Education
High school diploma (or GED) or less, n (%) 45 (22.3)
Some college or certification program, n (%) 81 (40.1)
College or university degree (2- or 4-year), n (%) 56 (27.7)
Graduate degree, n (%) 16 (7.9)
Other, n (%) 2 (1.0)
Missing/No response, n (%) 2 (1.0)
Patient rating of current severity of diarrhea-specific IBS
Very mild, n (%) 5 (2.5)
Mild, n (%) 46 (22.8)
Moderate, n (%) 106 (52.5)
Severe, n (%) 44 (21.8)
Very severe, n (%) 1 (0.5)
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response for a particular item on day 1. Floor effects
greater than the 10 % a priori criterion were present for all
of the daily symptom diary items except frequency of gas;
however, given that the highest percentage scoring at floor
for any one item was 17 %, the floor effects were consid-
ered marginal. No ceiling effects ([10 % scoring at ceil-
ing) were observed for any of the Daily Symptom Diary
items.
Inter-item correlations within the IBS-D Diary
Inter-item correlations were examined using data from
day 1 (Table 5). With the exception of correlations with
the frequency of gas and accidents items, moderate to
high inter-item correlations were observed among all
items of the IBS-D Daily Symptom Diary and Event Log
(day 1 range 0.67–0.90; Table 5). The inter-item corre-
lations were highest between the two items measuring
severity of abdominal pain and stomach pain (r = 0.90
for the daily report at day 1). These two items appear to
be redundant, suggesting one can be deleted. The corre-
lations of these two items with the items asking about
abdominal cramps and abdominal pressure were also close
to or above 0.80, suggesting all of these abdominal
symptoms are closely related. Of note, point bi-serial
correlation coefficients were generated between the IBS-D
Daily Symptom Diary item 7 (accidents) and IBS-D Daily
Symptom Diary at day 8. The range of correlations was
low (range 0.19–0.28). This finding is likely due to the
very low frequency of report for accidents on a given day.
As larger clinical datasets become available, it will be of
value to further investigate the relationship between this
item and others by using a known-groups approach and by
evaluating the variable over a longer period of time than
1 day.
Test–retest reliability
Test–retest reliability was evaluated by comparing 7-day
average scores of individual items on the IBS-D Daily
Symptom Diary and Event Log between weeks 1 and 4,
among 115 stable patients who reported ‘‘no change’’ from
baseline in their symptoms on the PGI-C Week at study
week 4. All abdominal symptom items except frequency of
gas met the threshold for test–retest reliability
(ICC C 0.70), with ICC scores from 0.78 to 0.83. The ICC
for frequency of gas was 0.66, marginally below the
threshold. Item 7 (accidents) used a Yes/No dichotomous
scale, and therefore, Cohen’s kappa statistics were gener-
ated for a single-day score rather than weekly scores.
Reliability results for item 7 were well below the threshold;
however, these results are reported only between day 22
and day 28. Accidents on a given day are reported with
very low frequency and daily symptoms are highly vari-
able, both of which will weaken the ICC.
For the IBS-D Symptom Event Log, the mean number
of events also met or surpassed the threshold of 0.70;
however, mean immediacy (ICC = 0.64) and stool con-
sistency (ICC = 0.66) narrowly missed the 0.70 threshold.
The ICC score for the incomplete evacuation question fell
short of the threshold (ICC = 0.46) (Table 6).
Construct validity: correlations between symptoms
and events (concurrent validity)
Moderate correlations were observed between immediacy
of need and all abdominal items (range 0.50–0.56) except
frequency of gas (0.32) (Table 7). The number of daily
events had small to moderate correlations with abdominal
pain (0.40) and abdominal cramps (0.41) but smaller cor-
relations with stomach pain (0.34) and bloating (0.29).
Mean stool consistency had small to moderate correlations
with all abdominal items except frequency of gas, where
the correlation was negligible (0.13). However, all
abdominal symptoms demonstrated very low correlations
with daily percentage of completely emptied bowels. Fre-
quency of gas yielded a low correlation with all event log
items (Table 7). Accidents at day 8 (results not shown) also
yielded low correlations with the event log items (range
-0.08 to -0.27).
Table 5 Inter-item correlations–Spearman correlations of IBS-D daily symptom diary items at day 1
IBS-D daily symptom diary item IBS-D daily symptom diary item
Abdominal pain Stomach pain Abdominal cramps Abdominal pressure Bloated Frequency of gas
Abdominal pain 1.000 – – – – –
Stomach pain 0.904 1.000 – – – –
Abdominal cramps 0.824 0.807 1.000 – – –
Abdominal pressure 0.862 0.822 0.789 1.000 – –
Bloated 0.748 0.724 0.674 0.790 1.000 –
Frequency of gas 0.362 0.370 0.310 0.382 0.462 1.000
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Construct validity: correlations with generic and disease-
specific measures (concurrent validity)
A logical pattern of correlations was also observed between
IBS-D Daily Symptom Diary items and the concurrent
scores at day 8 (Table 8). As hypothesized, correlations
among the domains of the SF-12 and the IBS-D Daily
Symptom Diary items were extremely low for all SF-12
domains except ‘‘bodily pain,’’ which was moderately
correlated with the IBS-D Daily Symptom Diary items
related to abdominal pain, stomach pain, and abdominal
cramps (range -0.42 to -0.48). Correlations were not
calculated for the accidents item.
As expected for the disease-specific measures, moderate
correlations were observed between IBS-QOL domains and
the individual symptom items of the IBS-D Daily Symp-
tom Diary, except the IBS-QOL sexual domain, for which
correlations were low (range -0.27 to -0.33). Also as
expected, the IBS-D Daily Symptom Diary items all cor-
related most highly with the only concurrent symptom
measure, the IBS-SSS, ranging from 0.53 to 0.57 for all
items except frequency of gas, which was correlated with
the IBS-SSS at 0.32 but which was found to have low
correlations with all concurrent domains. Overall, a logical
pattern of correlations supported the validity of the Daily
Symptom Diary items as measures of IBS symptoms.
Construct validity: clinical (known-groups) validity
Statistically significant differences in each of the IBS-D
Daily Symptom Diary item scores were observed between
groups defined by patients’ ratings on the PGI-S as none/
mild, moderate, or severe/very severe. All IBS-D Daily
Symptom Diary item scores increased monotonically
across the PGI-S-defined groups, indicating that patients
reporting worse global severity ratings also had worse
symptoms scores on the diary (Fig. 2). With regard to the
accidents item (results not shown), a greater number and
percentage of patients in the severe/very severe group
(n = 26, 60.47 %) reported having accidents compared
with the moderate group (n = 20, 21.05 %), with the
fewest number of patients reporting accidents in the none/
mild group (n = 6, 10.71 %). Despite the difference in the
day of data collection (day 8 for the PGI-S vs. the 7 days
Table 6 Test–retest
reliability—study week 1 and
study week 4 (stable group)
PRO score N Reliability–ICC (95 % confidence interval)
IBS-D Daily Symptom Diary weekly mean scores
Mean abdominal pain 115 0.778 (0.695–0.841)
Mean stomach pain 115 0.789 (0.708–0.849)
Mean abdominal cramps 115 0.795 (0.717–0.854)
Mean abdominal pressure 115 0.813 (0.740–0.866)
Mean bloated 115 0.834 (0.769–0.882)
Mean frequency of gas 115 0.655 (0.537–0.748)
Accidentsa 160 0.174 (–0.165 to 0.513)
IBS-D Symptom Event Log weekly mean scores
Mean total events 110 0.834 (0.766–0.883)
Mean immediacy 110 0.642 (0.518–0.740)
Mean consistency 110 0.659 (0.539–0.753)
Mean percent of completely empty bowels 110 0.455 (0.294–0.591)
a Test-retest was run for the ‘‘accidents’’ item between days 22 and 28
Table 7 Spearman correlations between the IBS-D daily symptom diary and event log at week 1











Mean number of daily events 0.397 0.336 0.408 0.375 0.292 0.219
Average daily mean immediacy of need 0.526 0.499 0.521 0.558 0.545 0.321
Average daily mean consistency of the bowel
movement
0.398 0.361 0.401 0.411 0.354 0.128
Mean daily percentage of completely emptied
bowels
-0.161 -0.136 -0.144 -0.127 -0.231 -0.242
a Italics indicates moderate correlations
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prior for the accident item), these results are quite strong,
indicating item 7 should be evaluated carefully in future
analyses with an eye toward how it might best be incor-
porated into scoring with the ordinal rating scale items.
Patients experiencing a flare day reported significantly
higher symptom severity on each of the IBS-D Daily
Symptom Diary items except for frequency of gas (Fig. 3).
Discussion
The goal of this study was to psychometrically assess the
initial, item-level measurement properties of the IBS-D
Daily Symptom Diary and Event Log items.
The descriptive statistics showed minimal missing data
and good response distributions, suggesting the response
scales were fully utilized. Floor effects were slightly higher
than predicted for all items except one, but still considered
acceptable given that they were evaluated using data from
a single day; IBS-D symptoms are highly variable and high
symptom severity is not expected as a daily occurrence.
The proportion of subjects scoring at ceiling was minimal.
Test–retest reliability of the IBS-D Daily Symptom
Diary and Event Log met threshold for all items with the
exception of gas (ICC = 0.66), mean immediacy
(ICC = 0.64), stool consistency (ICC = 0.66), and
incomplete evacuation (ICC = 0.46) items. As the ICC
scores for gas, immediacy, and stool consistency only
narrowly failed to meet the 0.70 threshold, these results are
not considered of concern because these are highly variable
symptoms. The low ICCs for incomplete evacuation and
accidents are of greater concern and should be reanalyzed
as additional data become available. In particular, given the
very low frequency of report of accidents on a given day,
test–retest reliability for accidents should be evaluated in a
larger clinical sample by looking at periods of time that
Table 8 Spearman correlations of IBS-D daily symptom diary at day 8 (a) IBS-QOL and (b) SF-12
Concurrent measures IBS-D Daily Symptom Diary itema
Item 1 Item 2 Item 3 Item 4 Item 5 Item 6
Abdominal pain Stomach pain Abdominal cramps Abdominal pressure Bloated Frequency of gas
IBS-QOLb
Dysphoria -0.452 -0.465 -0.458 -0.463 -0.497 -0.303
Interference with activity -0.427 -0.455 -0.442 -0.437 -0.478 -0.283
Body image -0.424 -0.403 -0.411 -0.436 -0.55 -0.334
Health worry -0.350 -0.414 -0.356 -0.406 -0.426 -0.248
Food avoidance -0.364 -0.405 -0.370 -0.403 -0.428 -0.257
Social reaction -0.410 -0.419 -0.379 -0.397 -0.464 -0.320
Sexual -0.308 -0.330 -0.319 -0.309 -0.323 -0.267
Relationships -0.413 -0.392 -0.417 -0.391 -0.391 -0.303
Overall -0.469 -0.486 -0.470 -0.481 -0.532 -0.347
Total score 0.553 0.552 0.525 0.542 0.573 0.319
SF-12c
Physical functioning -0.111 -0.136 -0.088 -0.112 -0.159 -0.166
Role physical -0.269 -0.286 -0.254 -0.271 -0.277 -0.262
Bodily pain -0.423 -0.475 -0.423 -0.377 -0.372 -0.302
General health -0.155 -0.154 -0.114 -0.136 -0.102 -0.147
Vitality -0.159 -0.128 -0.159 -0.204 -0.198 -0.179
Social functioning -0.311 -0.298 -0.269 -0.286 -0.318 -0.353
Role emotional -0.210 -0.216 -0.232 -0.285 -0.297 -0.266
Mental health -0.245 -0.208 -0.260 -0.284 -0.302 -0.247
Physical component scale -0.240 -0.289 -0.201 -0.187 -0.198 -0.204
Mental component scale -0.231 -0.199 -0.239 -0.283 -0.313 -0.272
Spearman correlation coefficients were generated between the IBS-D Daily Symptom Diary and concurrent measures
a IBS-D Daily Symptom Diary Items 1–5 are scored on a numeric rating scale from 0 to 10, with higher scores representing more severe
symptoms. IBS-D Daily Symptom Diary Item 6 is scored on a five choice ordinal scale with higher scores representing more frequent gas
b IBS-QOL scores range from 0 to 100, with higher scores representing better health states. The IBS-SSS total score ranges from 0 to 500 with
higher scores reflecting higher severity of IBS
c SF-12 scores range from 0 to 100, with higher scores representing better health states
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will be used as endpoints rather than looking at single-day
occurrences.
Inter-item correlations were highest between the two
items measuring severity of abdominal pain and stomach
pain, suggesting that the items are measuring very similar
concepts and are possibly redundant. This finding provides
evidence that patients may think that abdominal pain and
stomach pain are the same concept, which is consistent
with qualitative data in which patients were thinking about
the same part of their body when responding to these items
[15]. With regard to the qualitative data, six of the 11
subjects in the cognitive debriefing interviews stated that
the stomach pain and abdominal pain items were the same,
while only three reported a difference [15]. Further, when
patients indicated location on a diagram, there was no
consistent indication that patients made a distinction
between abdomen and stomach. Finally, given that
cramping and pressure items use the term ‘‘abdominal’’ and
considering that both pain items were well understood
during qualitative testing (i.e., cognitive debriefing), the
‘‘abdominal pain’’ item will be retained and the ‘‘stomach
pain’’ item removed [15].
The abdominal pain and stomach pain items were also
relatively closely related to the abdominal cramps and
abdominal pressure items. It could be argued that retention
of just the abdominal pain item is sufficient and that the
other three do not add great additional value. However, the
abdominal cramps item seemed to discriminate best
between flare and non-flare days in the known-groups
analyses, and so arguably it provides valuable additional
information. Therefore, all three items (abdominal pain,
cramps, and pressure) will be retained for further testing.
Evaluation of concurrent validity demonstrated a logical
pattern of correlations with concurrent measures, which
supports the validity of the IBS-D Daily Symptom Diary and
Event Log items as measures of IBS-D symptoms. In
accordance with predictions, the IBS-D Daily Symptom
Diary showed mostly low correlations with the HRQoL
questionnaires and higher, moderate correlations with the
IBS-SSS. Furthermore, the instrument correlated more
highly with the disease-specific IBS-QOL than with the
generic SF-12. The lack of overlap in recall periods between
the IBS-D Daily Symptom Diary and Event Log and the
concurrent measures is likely to have been a factor in
reducing the magnitude of some correlations. For example,
the IBS-QOL has a 4-week recall period, and thus, it is
perhaps not surprising that the correlation with a week
average of IBS-D Daily Symptom Diary item scores was low
in addition to content differences (i.e., a symptom-based
measure vs. a quality of life-based measure). Similar content
between the IBS-D Symptom Diary and the IBS-SSS is the
reasoning behind moderate correlations. Overall, these
findings support the concurrent validity of the instrument.
For all items on the IBS-D Daily Symptom Diary and
Event log, statistically significant differences in each of the
IBS-D Daily Symptom Diary item scores were observed
between groups defined by patients’ ratings on the PGI-S,
indicating that those patients with more severe IBS-D are
responding on the more severe end of the questionnaire’s
spectrum. These results provide strong evidence that the
different items of the IBS-D Daily Symptom Diary and
Event Log are able to discriminate among patients of dif-
fering severity.
The findings reported here, as well as the previously
conducted qualitative research, provide strong evidence in
support of the initial psychometric validity of the IBS-D
Daily Symptom Diary 24-h recall questions and the IBS-D
Symptom Event Log questions.
The next step is the creation of summary scores
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Fig. 2 IBS-D Daily Symptom Diary by PGI-S response at day 8.
IBS-D Daily Symptom Diary Items 1–5 are scored on a numeric
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Fig. 3 IBS-D Daily Symptom Diary by flare experience at day 1
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